Inhibition of matrix metalloproteinases and tumour necrosis factor alpha converting enzyme as adjuvant therapy in pneumococcal meningitis

Leib, Stephen L.; Clements, John M.; Lindberg, Raija L. P.; Heimgartner, Chris; Loeffler, Jutta M.; Pfister, Luz-Andrea; Täuber, Martin G.; Leppert, David (2001). Inhibition of matrix metalloproteinases and tumour necrosis factor alpha converting enzyme as adjuvant therapy in pneumococcal meningitis. Brain, 124(9), pp. 1734-1742. Oxford: Oxford University Press 10.1093/brain/124.9.1734

[img]
Preview
Text
Brain-2001-Leib-1734-42.pdf - Published Version
Available under License Publisher holds Copyright.

Download (332kB) | Preview

Matrix metalloproteinases (MMPs) and tumour necrosis factor alpha (TNF-alpha) converting enzyme (TACE) contribute synergistically to the pathophysiology of bacterial meningitis. TACE proteolytically releases several cell-surface proteins, including the proinflammatory cytokine TNF-alpha and its receptors. TNF-alpha in turn stimulates cells to produce active MMPs, which facilitate leucocyte extravasation and brain oedema by degradation of extracellular matrix components. In the present time-course studies of pneumococcal meningitis in infant rats, MMP-8 and -9 were 100- to 1000-fold transcriptionally upregulated, both in CSF cells and in brain tissue. Concentrations of TNF-alpha and MMP-9 in CSF peaked 12 h after infection and were closely correlated. Treatment with BB-1101 (15 mg/kg subcutaneously, twice daily), a hydroxamic acid-based inhibitor of MMP and TACE, downregulated the CSF concentration of TNF-alpha and decreased the incidences of seizures and mortality. Therapy with BB-1101, together with antibiotics, attenuated neuronal necrosis in the cortex and apoptosis in the hippocampus when given as a pretreatment at the time of infection and also when administration was started 18 h after infection. Functionally, the neuroprotective effect of BB-1101 preserved learning performance of rats assessed 3 weeks after the disease had been cured. Thus, combined inhibition of MMP and TACE offers a novel therapeutic strategy to prevent brain injury and neurological sequelae in bacterial meningitis.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Service Sector > Institute for Infectious Diseases

UniBE Contributor:

Leib, Stephen, Täuber, Martin G.

Subjects:

500 Science > 570 Life sciences; biology
600 Technology > 610 Medicine & health

ISSN:

0006-8950

ISBN:

11522576

Publisher:

Oxford University Press

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 15:00

Last Modified:

05 Dec 2022 14:18

Publisher DOI:

10.1093/brain/124.9.1734

PubMed ID:

11522576

Web of Science ID:

000171312800006

Uncontrolled Keywords:

bacterial meningitis, matrix metalloproteinases, neuronal injury, learning, hydroxamic acid inhibitors

BORIS DOI:

10.7892/boris.25739

URI:

https://boris.unibe.ch/id/eprint/25739 (FactScience: 60846)

Actions (login required)

Edit item Edit item
Provide Feedback